[9/7/19, rond-point des Champs-Élysées, canons allemands entassés pour les préparatifs de la Victoire] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54807

[9/7/19, rond-point des Champs-Élysées, canons allemands entassés pour les préparatifs de la Victoire] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54808

Paraoxonase2 polymorphisms are associated with nephropathy in Type II diabetes.

AIMS/HYPOTHESIS: Paraoxonase is a member of a multigene family of three genes. Paraoxonase2 gene polymorphisms have been associated with coronary heart disease in non-diabetic patients and with an increased fasting glycaemia in patients with Type II (non-insulin-dependent) diabetes mellitus. We tested the hypothesis of whether paraoxonase1 and paraoxonase2 polymorphisms were associated with diabetic nephropathy. METHODS: Our case-control study of 299 Swiss patients with Type II diabetes included 147 patients with confirmed diabetic nephropathy. RESULTS: In univariate analyses the two paraoxonase2 polymorphisms were associated with diabetic nephropathy. When subjected to multivariate analyses, both paraoxonase2 polymorphisms remained statistically associated with diabetic nephropathy independent of traditional risk factors (paraoxonase2-148: OR = 2.53, p = 0.003; paraoxonase2-311: OR = 2.67, p = 0.002). In addition, BMI interacted with paraoxonase2 polymorphisms as a risk factor of nephropathy. CONCLUSIONS/INTERPRETATION: The paraoxonase2 gene polymorphisms were significantly associated with diabetic nephropathy independent of traditional risk factors in Type II diabetic patients. The susceptibility to diabetic nephropathy was intensified by the degree of obesity. Pathophysiological pathways should be investigated and could be involved in insulin resistance or lipids metabolism or both.

1.° L. Annaei Senecae tragoediae decem, cum scholiis. — 2.° P. Ovidii Nasonis de arte amandi libri tres, cum scholiis. — 3.° Ejusdem liber de remedio amoris, cum scholiis. — 4.° Moretum, quod carmen Virgilio tribuitur : accedunt scholia. — 5.° Senecae liber de vera amicitia, cum scholiis. — 6.° Virgilii bucolica, cum scholiis. — 7.° Rosae, quod carmen Virgilio tribuitur.

Petri de Carcavi

1.° Caii Plinii Secundi epistolarum libri decem : primi initium et decimi finis desiderantur. — 2.° Ejusdem panegyricus Trajano dictus. — 3.° Latini Pacati Drepanii panegyricus Theodosio dictus. — 4.° Claudii Mamertini Juliano Imperatori gratiarum actio de Consulatu suo. — 5.° Nazarii panegyricus Constantino, Caesari, dictus. — 6.° Eumenii gratiarum actio Constantino, Augusto, Flaviensium nomine. — 7.° Ejusdem panegyricus Constantino, Augusto, dictus. — 8.° Incerti authoris panegyricus Maximiano et Constantino dictus. — 9.° Eumenii panegyricus Constantio, Caesari, dictus. — 10.° Ejusdem oratio pro restaurandis scholis. — 11.° Claudii Mamertini panegyricus Maximiano, Augusto, dictus. — 12.° Genethliacus Maximiani : authore eodem. — 13.° Incerti authoris panegyricus Constantino, Augusto, dictus : finis desideratur.

Bigotianus

Prevalence, characteristics, and publication of discontinued randomized trials.

IMPORTANCE: The discontinuation of randomized clinical trials (RCTs) raises ethical concerns and often wastes scarce research resources. The epidemiology of discontinued RCTs, however, remains unclear. OBJECTIVES: To determine the prevalence, characteristics, and publication history of discontinued RCTs and to investigate factors associated with RCT discontinuation due to poor recruitment and with nonpublication. DESIGN AND SETTING: Retrospective cohort of RCTs based on archived protocols approved by 6 research ethics committees in Switzerland, Germany, and Canada between 2000 and 2003. We recorded trial characteristics and planned recruitment from included protocols. Last follow-up of RCTs was April 27, 2013. MAIN OUTCOMES AND MEASURES: Completion status, reported reasons for discontinuation, and publication status of RCTs as determined by correspondence with the research ethics committees, literature searches, and investigator surveys. RESULTS: After a median follow-up of 11.6 years (range, 8.8-12.6 years), 253 of 1017 included RCTs were discontinued (24.9% [95% CI, 22.3%-27.6%]). Only 96 of 253 discontinuations (37.9% [95% CI, 32.0%-44.3%]) were reported to ethics committees. The most frequent reason for discontinuation was poor recruitment (101/1017; 9.9% [95% CI, 8.2%-12.0%]). In multivariable analysis, industry sponsorship vs investigator sponsorship (8.4% vs 26.5%; odds ratio [OR], 0.25 [95% CI, 0.15-0.43]; P < .001) and a larger planned sample size in increments of 100 (-0.7%; OR, 0.96 [95% CI, 0.92-1.00]; P = .04) were associated with lower rates of discontinuation due to poor recruitment. Discontinued trials were more likely to remain unpublished than completed trials (55.1% vs 33.6%; OR, 3.19 [95% CI, 2.29-4.43]; P < .001). CONCLUSIONS AND RELEVANCE: In this sample of trials based on RCT protocols from 6 research ethics committees, discontinuation was common, with poor recruitment being the most frequently reported reason. Greater efforts are needed to ensure the reporting of trial discontinuation to research ethics committees and the publication of results of discontinued trials.

The biochemistry of drug metabolism-an introduction: part 7. Intra-individual factors affecting drug metabolism.

This review on intra-individual factors affecting drug metabolism completes our series on the biochemistry of drug metabolism. The article presents the molecular mechanisms causing intra-individual differences in enzyme expression and activity. They include enzyme induction by transcriptional activation and enzyme inhibition on the protein level. The influencing factors are of physiological, pathological, or external origin. Tissue characteristics and developmental age strongly influence enzyme-expression patterns. Further influencing factors are pregnancy, disease, or biological rhythms. Xenobiotics, drugs, constituents of herbal remedies, food constituents, ethanol, and tobacco can all influence enzyme expression or activity and, hence, affect drug metabolism.